Assessing the importance of domestic vaccine manufacturing centers: An overview of immunization programs, vaccine manufacture, and distribution

Emma Rey-Jurado, Felipe Tapia, Natalia Muñoz-Durango, Margarita K. Lay, Leandro J. Carreño, Claudia A. Riedel, Susan M. Bueno, Yvonne Genzel, Alexis M. Kalergis

Resultado de la investigación: Review article

4 Citas (Scopus)

Resumen

Vaccines have significantly reduced the detrimental effects of numerous human infectious diseases worldwide, helped to reduce drastically child mortality rates and even achieved eradication of major pathogens, such as smallpox. These achievements have been possible due to a dedicated effort for vaccine research and development, as well as an effective transfer of these vaccines to public health care systems globally. Either public or private institutions have committed to developing and manufacturing vaccines for local or international population supply. However, current vaccine manufacturers worldwide might not be able to guarantee sufficient vaccine supplies for all nations when epidemics or pandemics events could take place. Currently, different countries produce their own vaccine supplies under Good Manufacturing Practices, which include the USA, Canada, China, India, some nations in Europe and South America, such as Germany, the Netherlands, Italy, France, Argentina, and Brazil, respectively. Here, we discuss some of the vaccine programs and manufacturing capacities, comparing the current models of vaccine management between industrialized and developing countries. Because local vaccine production undoubtedly provides significant benefits for the respective population, the manufacture capacity of these prophylactic products should be included in every country as a matter of national safety.

Idioma originalEnglish
Número de artículo26
PublicaciónFrontiers in Immunology
Volumen9
N.ºJAN
DOI
EstadoPublished - 18 ene 2018

Huella dactilar

Immunization Programs
Vaccines
Child Mortality
Smallpox
South America
Argentina
Pandemics
Developed Countries
Netherlands
Italy
Population
Developing Countries
France
Canada
Communicable Diseases
Germany
Brazil
India
China
Public Health

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Citar esto

Rey-Jurado, Emma ; Tapia, Felipe ; Muñoz-Durango, Natalia ; Lay, Margarita K. ; Carreño, Leandro J. ; Riedel, Claudia A. ; Bueno, Susan M. ; Genzel, Yvonne ; Kalergis, Alexis M. / Assessing the importance of domestic vaccine manufacturing centers : An overview of immunization programs, vaccine manufacture, and distribution. En: Frontiers in Immunology. 2018 ; Vol. 9, N.º JAN.
@article{b4f29b28e6c149ed879eeada9465280a,
title = "Assessing the importance of domestic vaccine manufacturing centers: An overview of immunization programs, vaccine manufacture, and distribution",
abstract = "Vaccines have significantly reduced the detrimental effects of numerous human infectious diseases worldwide, helped to reduce drastically child mortality rates and even achieved eradication of major pathogens, such as smallpox. These achievements have been possible due to a dedicated effort for vaccine research and development, as well as an effective transfer of these vaccines to public health care systems globally. Either public or private institutions have committed to developing and manufacturing vaccines for local or international population supply. However, current vaccine manufacturers worldwide might not be able to guarantee sufficient vaccine supplies for all nations when epidemics or pandemics events could take place. Currently, different countries produce their own vaccine supplies under Good Manufacturing Practices, which include the USA, Canada, China, India, some nations in Europe and South America, such as Germany, the Netherlands, Italy, France, Argentina, and Brazil, respectively. Here, we discuss some of the vaccine programs and manufacturing capacities, comparing the current models of vaccine management between industrialized and developing countries. Because local vaccine production undoubtedly provides significant benefits for the respective population, the manufacture capacity of these prophylactic products should be included in every country as a matter of national safety.",
keywords = "Good manufacturing practices, Immunization programs, Vaccine distribution, Vaccine manufacturing, Vaccine shortages",
author = "Emma Rey-Jurado and Felipe Tapia and Natalia Mu{\~n}oz-Durango and Lay, {Margarita K.} and Carre{\~n}o, {Leandro J.} and Riedel, {Claudia A.} and Bueno, {Susan M.} and Yvonne Genzel and Kalergis, {Alexis M.}",
year = "2018",
month = "1",
day = "18",
doi = "10.3389/fimmu.2018.00026",
language = "English",
volume = "9",
journal = "Frontiers in Immunology",
issn = "1664-3224",
publisher = "Frontiers Media S.A.",
number = "JAN",

}

Assessing the importance of domestic vaccine manufacturing centers : An overview of immunization programs, vaccine manufacture, and distribution. / Rey-Jurado, Emma; Tapia, Felipe; Muñoz-Durango, Natalia; Lay, Margarita K.; Carreño, Leandro J.; Riedel, Claudia A.; Bueno, Susan M.; Genzel, Yvonne; Kalergis, Alexis M.

En: Frontiers in Immunology, Vol. 9, N.º JAN, 26, 18.01.2018.

Resultado de la investigación: Review article

TY - JOUR

T1 - Assessing the importance of domestic vaccine manufacturing centers

T2 - An overview of immunization programs, vaccine manufacture, and distribution

AU - Rey-Jurado, Emma

AU - Tapia, Felipe

AU - Muñoz-Durango, Natalia

AU - Lay, Margarita K.

AU - Carreño, Leandro J.

AU - Riedel, Claudia A.

AU - Bueno, Susan M.

AU - Genzel, Yvonne

AU - Kalergis, Alexis M.

PY - 2018/1/18

Y1 - 2018/1/18

N2 - Vaccines have significantly reduced the detrimental effects of numerous human infectious diseases worldwide, helped to reduce drastically child mortality rates and even achieved eradication of major pathogens, such as smallpox. These achievements have been possible due to a dedicated effort for vaccine research and development, as well as an effective transfer of these vaccines to public health care systems globally. Either public or private institutions have committed to developing and manufacturing vaccines for local or international population supply. However, current vaccine manufacturers worldwide might not be able to guarantee sufficient vaccine supplies for all nations when epidemics or pandemics events could take place. Currently, different countries produce their own vaccine supplies under Good Manufacturing Practices, which include the USA, Canada, China, India, some nations in Europe and South America, such as Germany, the Netherlands, Italy, France, Argentina, and Brazil, respectively. Here, we discuss some of the vaccine programs and manufacturing capacities, comparing the current models of vaccine management between industrialized and developing countries. Because local vaccine production undoubtedly provides significant benefits for the respective population, the manufacture capacity of these prophylactic products should be included in every country as a matter of national safety.

AB - Vaccines have significantly reduced the detrimental effects of numerous human infectious diseases worldwide, helped to reduce drastically child mortality rates and even achieved eradication of major pathogens, such as smallpox. These achievements have been possible due to a dedicated effort for vaccine research and development, as well as an effective transfer of these vaccines to public health care systems globally. Either public or private institutions have committed to developing and manufacturing vaccines for local or international population supply. However, current vaccine manufacturers worldwide might not be able to guarantee sufficient vaccine supplies for all nations when epidemics or pandemics events could take place. Currently, different countries produce their own vaccine supplies under Good Manufacturing Practices, which include the USA, Canada, China, India, some nations in Europe and South America, such as Germany, the Netherlands, Italy, France, Argentina, and Brazil, respectively. Here, we discuss some of the vaccine programs and manufacturing capacities, comparing the current models of vaccine management between industrialized and developing countries. Because local vaccine production undoubtedly provides significant benefits for the respective population, the manufacture capacity of these prophylactic products should be included in every country as a matter of national safety.

KW - Good manufacturing practices

KW - Immunization programs

KW - Vaccine distribution

KW - Vaccine manufacturing

KW - Vaccine shortages

UR - http://www.scopus.com/inward/record.url?scp=85040989472&partnerID=8YFLogxK

U2 - 10.3389/fimmu.2018.00026

DO - 10.3389/fimmu.2018.00026

M3 - Review article

AN - SCOPUS:85040989472

VL - 9

JO - Frontiers in Immunology

JF - Frontiers in Immunology

SN - 1664-3224

IS - JAN

M1 - 26

ER -